ArticleLancet regional health. Americas2026
Trends and disparities of vision impairment in Mexico from 1990 to 2023: a comparative analysis with Latin America and the Caribbean based on the Global Burden of Disease Study 2023.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The growing global burden of blindness and vision loss underscores the importance of understanding regional and national epidemiological patterns and trends. This observational study examined the burden of vision impairment in Mexico in 2023 and evaluated trends from 1990 to 2023, comparing with regional estimates for Latin America & Caribbean (LAC). Methods: Using data from the Global Burden of Disease study 2023 (GBD 2023), aggregated estimates for the total population (all ages and sexes) of LAC (comprising 33 countries and territories) and Mexico (comprising 32 states) were analyzed from 1990 to 2023. Counts and age-standardized rates (per 100,000) of prevalent cases and years lived with disability (YLDs) for total vision impairment including four levels of severity were examined for LAC and Mexico (nationally and subnationally), analyzing percentage change from 1990 to 2023. Findings: In 2023, blindness and vision loss caused an estimated 61.58 million and 14.15 million prevalent cases in LAC and Mexico, respectively, increasing 162% and 172% from 1990, constituting the third leading cause of impairment at both levels, surpassed by hearing loss and anemia. Uncorrected presbyopia and moderate vision loss accounted for 89% of prevalent cases, while severe vision loss and blindness contributed 50% of the YLDs. From 1990 to 2023, the age-standardized rate of all severity levels decreased; regionally, total vision impairment caused 9410 cases (per 100,000) in 2023, a decline of -5.92% from 1990, whereas blindness alone decreased by -35.65%, with 523 cases per 100,000 in 2023. Across Mexico's 32 states, the burden exhibited a consistent downward trajectory with disparate percentages of change, demonstrating subnational heterogeneity. Interpretation: We documented an increased burden of vision impairment in LAC and Mexico, highlighting the need for targeted interventions, expanded access to vision care, and strengthened preventive measures. Addressing disparities through equitable healthcare distribution and awareness campaigns could reduce the burden of vision loss. Funding: This study received no funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.